Advertisement

European Journal of Clinical Pharmacology

, Volume 43, Issue 1, pp 105–107 | Cite as

Pharmacokinetics of ofloxacin in elderly patients and in healthy young subjects

  • M. Molinaro
  • P. Villani
  • M. B. Regazzi
  • R. Rondanelli
  • G. Doveri
Short Communications

Summary

The pharmacokinetics of ofloxacin, a fluoroquinolone widely used in the treatment of bacterial infections, may be different according to age, owing to the biological differences that exist between an elderly organism and a young subject, expecially as regards the renal and the hepatic function.

In our study the pharmacokinetics of ofloxacin in 12 elderly patients was found to be different from those of 12 healthy young volunteers.

The elimination half-life (t½) was slightly shorter in the young subjects than in the elderly: 6.2 (0.9)h against 8.5(1.2)h respectively. The oral total clearance was lower in the geriatric patients compared to the young healthy volunteers: 83.3(16.6) ml/min in the first group, and 23.3(33.3) ml/min in the second group. AUC and peak plasma concentration in elderly exceeded those noted in young healthy volunteers.

The results of this study suggest that, compared with younger subjects, older patients experience delayed elimination of ofloxacin. It would be reasonable, from a pharmacokinetic point of view, to limit the dose of ofloxacin in patients more than 75 years old, at least to one half of that given to younger patients.

Key words

Ofloxacin pharmacokinetic geriatric patients young healthy volunteers 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Monk JP, Campoli-Richards DM (1987) Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 33: 346–391Google Scholar
  2. 2.
    Wolfson JS, Hooper DC (1985) The fluoroquinolones: structures, mechanism of action and resistence, and spectra of activity in vitro. Antimicrob Agents Chemother 28: 581–586Google Scholar
  3. 3.
    Bergeron MG (1989) The pharmacokinetics and tissue penetration of the fuoroquinolones. Clin Invest Med 12: 20–27Google Scholar
  4. 4.
    Lode H, Hoffken G, Olschewski P, Sievers B, Kirch A, Koeppe P (1987) Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother 31: 1338–1342Google Scholar
  5. 5.
    Veissier P, Fourtillan JB, Modai J, Couet W, Lefebvre MA, Darchis JP, Vincent Du Laurier M, Bryskier A (1986) Pharmacocinetique de l'ofloxacine chez le sujet age (65 a 85 ans) a function renale apres prise oral unique de 200 mg. Pathol Biol 34: 569–599Google Scholar
  6. 6.
    Rademaker CMA, Jones RW, Notarianni LJ, Van Dijk A, Glerum JH, Verhocf J (1989) Pharmacokinetics of a single dose of ofloxacin in healthy elderly subjects using noncompartmental and compartmental models. Pharm Weekbl [Sci] 11: 224–228Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • M. Molinaro
    • 1
  • P. Villani
    • 1
  • M. B. Regazzi
    • 1
  • R. Rondanelli
    • 2
  • G. Doveri
    • 1
  1. 1.Department of PharmacologyIRCCS Policlinico S. MatteoPaviaItaly
  2. 2.University of PaviaPaviaItaly

Personalised recommendations